MX2013006732A - 19-noresteroides novedosos y su uso para tratar condiciones que dependen de progesterona. - Google Patents
19-noresteroides novedosos y su uso para tratar condiciones que dependen de progesterona.Info
- Publication number
- MX2013006732A MX2013006732A MX2013006732A MX2013006732A MX2013006732A MX 2013006732 A MX2013006732 A MX 2013006732A MX 2013006732 A MX2013006732 A MX 2013006732A MX 2013006732 A MX2013006732 A MX 2013006732A MX 2013006732 A MX2013006732 A MX 2013006732A
- Authority
- MX
- Mexico
- Prior art keywords
- steroids
- novel
- treating
- dependent conditions
- conditions
- Prior art date
Links
- 230000001419 dependent effect Effects 0.000 title abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title 2
- 229960003387 progesterone Drugs 0.000 title 1
- 239000000186 progesterone Substances 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/062068 WO2011119194A1 (en) | 2010-03-22 | 2010-12-23 | Compositions and methods for non-toxic delivery of antiprogestins |
| PCT/US2011/050859 WO2012087389A1 (en) | 2010-12-23 | 2011-09-08 | Novel 19-nor-steroids and their use for treating progesterone-dependent conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013006732A true MX2013006732A (es) | 2013-07-17 |
Family
ID=44681424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013006732A MX2013006732A (es) | 2010-12-23 | 2011-09-08 | 19-noresteroides novedosos y su uso para tratar condiciones que dependen de progesterona. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130274234A1 (enExample) |
| EP (1) | EP2655394A1 (enExample) |
| JP (2) | JP2014500316A (enExample) |
| KR (1) | KR20130132955A (enExample) |
| CN (1) | CN103403017A (enExample) |
| AU (1) | AU2011345341B2 (enExample) |
| CA (1) | CA2820877A1 (enExample) |
| MX (1) | MX2013006732A (enExample) |
| NZ (1) | NZ612295A (enExample) |
| SG (1) | SG191207A1 (enExample) |
| UA (1) | UA113283C2 (enExample) |
| WO (1) | WO2012087389A1 (enExample) |
| ZA (1) | ZA201304381B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2854763B1 (en) | 2012-05-31 | 2018-09-26 | Repros Therapeutics Inc. | Formulations for vaginal delivery of antiprogestins |
| JP6343619B2 (ja) * | 2012-11-02 | 2018-06-13 | レプロス セラピューティクス インコーポレイティド | プロゲステロン依存性病態を処置する方法およびその組成物 |
| CN106232107B (zh) * | 2014-05-05 | 2020-06-05 | 艾尔建制药国际有限公司 | 用于抗孕激素的阴道递送的制剂和方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| ATE151286T1 (de) | 1983-11-14 | 1997-04-15 | Columbia Lab Inc | Bioadhäsive mittel |
| FR2573657B1 (fr) * | 1984-11-29 | 1989-05-12 | Roussel Uclaf | Produit comprenant une substance antiprogestomimetique et une substance uterotonique |
| US4954490A (en) * | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| DE69702450T2 (de) * | 1996-05-01 | 2001-03-08 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | 21-substituierte progesteron derivate als antigestagene |
| US6900193B1 (en) * | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| DK1265911T3 (da) * | 2000-03-17 | 2008-09-29 | Us Gov Health & Human Serv | 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler |
| ES2643318T3 (es) * | 2006-10-24 | 2017-11-22 | Repros Therapeutics Inc. | Composiciones y métodos para suprimir la proliferación endometrial |
| US20090118253A1 (en) * | 2007-11-05 | 2009-05-07 | Repros Therapeutics Inc. | Compositions and methods for treating dysfunctional uterine bleeding |
| TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| TWI539953B (zh) * | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
-
2011
- 2011-08-09 UA UAA201309244A patent/UA113283C2/uk unknown
- 2011-09-08 AU AU2011345341A patent/AU2011345341B2/en not_active Ceased
- 2011-09-08 CA CA2820877A patent/CA2820877A1/en not_active Abandoned
- 2011-09-08 EP EP11761438.8A patent/EP2655394A1/en not_active Withdrawn
- 2011-09-08 KR KR1020137019568A patent/KR20130132955A/ko not_active Ceased
- 2011-09-08 NZ NZ612295A patent/NZ612295A/en not_active IP Right Cessation
- 2011-09-08 JP JP2013546126A patent/JP2014500316A/ja not_active Withdrawn
- 2011-09-08 WO PCT/US2011/050859 patent/WO2012087389A1/en not_active Ceased
- 2011-09-08 MX MX2013006732A patent/MX2013006732A/es unknown
- 2011-09-08 US US13/997,097 patent/US20130274234A1/en not_active Abandoned
- 2011-09-08 CN CN2011800682607A patent/CN103403017A/zh active Pending
- 2011-09-08 SG SG2013046602A patent/SG191207A1/en unknown
-
2013
- 2013-06-13 ZA ZA2013/04381A patent/ZA201304381B/en unknown
-
2016
- 2016-07-08 JP JP2016135644A patent/JP2016180004A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201304381B (en) | 2014-03-26 |
| US20130274234A1 (en) | 2013-10-17 |
| AU2011345341A1 (en) | 2013-07-04 |
| JP2014500316A (ja) | 2014-01-09 |
| EP2655394A1 (en) | 2013-10-30 |
| JP2016180004A (ja) | 2016-10-13 |
| WO2012087389A1 (en) | 2012-06-28 |
| CN103403017A (zh) | 2013-11-20 |
| SG191207A1 (en) | 2013-07-31 |
| UA113283C2 (xx) | 2017-01-10 |
| KR20130132955A (ko) | 2013-12-05 |
| NZ612295A (en) | 2014-07-25 |
| CA2820877A1 (en) | 2012-06-28 |
| AU2011345341B2 (en) | 2016-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN00848A (enExample) | ||
| MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
| PH12017502141A1 (en) | Compounds and their methods of use | |
| EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| PH12013501176A1 (en) | Novel 19-nor-steroids and their use for treating progesterone-dependent conditions | |
| EA201491412A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| MX2020010639A (es) | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer. | |
| CL2015001508A1 (es) | Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros. | |
| EA201591145A1 (ru) | Ингибиторы гистондеметилазы | |
| EA201792465A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201200999A1 (ru) | Способы лечения рака молочной железы | |
| EA201490944A1 (ru) | Двойной ингибитор met и vegf для лечения рака | |
| PH12015501243B1 (en) | Compositions and methods for antibodies targeting epo | |
| PH12015501997A1 (en) | Compositions and methods for diagnosis and treatment of hepatic cancers | |
| TN2012000469A1 (en) | Use of novel pan-cdk inhibitors for treating tumors | |
| EA201500851A1 (ru) | ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3) | |
| PH12013501018A1 (en) | 177lutetium-labeled bombesin analogs for radiotherapy | |
| EA201490180A1 (ru) | Антитела к erbb3 в комбинации с паклитакселом для лечения гинекологических злокачественных заболеваний | |
| EA201170447A1 (ru) | Производные изохинолинона в качестве антагонистов nk3 | |
| MX2015004821A (es) | Metodos y composiciones para tratar condiciones dependientes de la progesterona. | |
| MX391523B (es) | Intermediarios y metodos para sintetizar derivados de calicheamicina | |
| WO2014079931A8 (en) | Cd44v6-derived peptides for treating breast cancers | |
| RU2009123421A (ru) | Способ применения наноформы транс-резвератрола для лечения и профилактики гормонозависимых пролиферативных процессов, в том числе опухолей | |
| IN2012DN02721A (enExample) | ||
| IN2013CH05409A (enExample) |